Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease

Phase 2positivetulisokibartHumiraBimzelxPositive

AI Analysis

Summary

Merck released detailed Phase 2 trial data for tulisokibart in hidradenitis suppurativa, with analysts noting the data is 'highly competitive' and could establish the drug in a market already served by AbbVie's Humira and UCB's Bimzelx.

Clinical Trial Data

Phase

Outcome Details

mid-stage trial data described as 'highly competitive' by analysts

Importance:6/10

Sentiment:

0.70

dermatologyantibodyhidradenitis suppurativaPhase 2competitive positioning

Related Companies

$MRK

Read the original article

Published by BioSpace on October 1, 2026 3:24 PM

Read Original